Literature DB >> 27624768

[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

A Brinkmann1, A C Röhr2, A Köberer3, T Fuchs3, J Preisenberger2, W A Krüger4, O R Frey2.   

Abstract

Pharmacokinetic variability of anti-infective drugs due to pathophysiological changes by severe sepsis and septic shock is a well-known problem for critically ill patients resulting in suboptimal serum and most likely tissue concentrations of these agents.To cover a wide range of potential pathogens, high concentrations of broad spectrum anti-infectives have to reach the site of infection. Microbiological susceptibility testing (susceptible, intermediate, resistant) don't take the pharmacokinetic variability into account and are based on data generated by non-critically ill patients. But inter-patient variability in distribution and elimination of anti-infective drugs in ICU patients is extremely high and also highly unpredictable. Drug clearance of mainly renally eliminated drugs and thus the required dose can differ up to 10-fold due to the variability in renal function in patients with severe infections. To assure a timely and adequate anti-infective regime, individual dosing and therapeutic drug monitoring (TDM) seem to be appropriate tools in the setting of pathophysiological changes in pharmacokinetics (PK) and pharmakodynamics (PD) due to severe sepsis. In the case of known minimal inhibitory concentration, PK/PD indices (time or peak concentration dependent activity) and measured serum level can provide an optimal target concentration for the individual drug and patient.Modern anti-infective management for ICU patients includes more than the choice of drug and prompt application. Individual dosing, optimized prolonged infusion time and TDM give way to new and promising opportunities in infection control.

Entities:  

Keywords:  Antiinfektive drugs; Intensive care medicine; Septic shock; Severe sepsis; Therapeutic drug monitoring; β-lactam-antibiotics

Mesh:

Substances:

Year:  2016        PMID: 27624768     DOI: 10.1007/s00063-016-0213-5

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  80 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 3.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

4.  Anti-infective drugs during continuous hemodialysis - using the bench to learn what to do at the bedside.

Authors:  Anka C Roehr; Otto R Frey; Andreas Koeberer; Thomas Fuchs; Jason A Roberts; Alexander Brinkmann
Journal:  Int J Artif Organs       Date:  2015-01-23       Impact factor: 1.595

5.  Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.

Authors:  G L Drusano; T P Lodise; D Melnick; W Liu; A Oliver; A Mena; B VanScoy; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 6.  Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation.

Authors:  Janattul-Ain Jamal; Caleb J P Economou; Jeffrey Lipman; Jason A Roberts
Journal:  Curr Opin Crit Care       Date:  2012-10       Impact factor: 3.687

7.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

Authors:  Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

8.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

9.  Vital organ blood flow during hyperdynamic sepsis.

Authors:  David Di Giantomasso; Clive N May; Rinaldo Bellomo
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

Review 10.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

View more
  8 in total

1.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

Review 2.  [Adequate anti-infective treatment : Importance of individual dosing and application].

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; W A Krüger; C König; D Richter; M A Weigand; O R Frey
Journal:  Anaesthesist       Date:  2018-06       Impact factor: 1.041

3.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

Review 4.  Bacterial sepsis : Diagnostics and calculated antibiotic therapy.

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Kruger; K Mayer; M W Pletz; D Storzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

Review 5.  [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Krüger; K Mayer; M W Pletz; D Störzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; Christoph Lichtenstern
Journal:  Anaesthesist       Date:  2017-10       Impact factor: 1.041

Review 6.  Quality indicators in intensive care medicine for Germany - third edition 2017.

Authors:  Oliver Kumpf; Jan-Peter Braun; Alexander Brinkmann; Hanswerner Bause; Martin Bellgardt; Frank Bloos; Rolf Dubb; Clemens Greim; Arnold Kaltwasser; Gernot Marx; Reimer Riessen; Claudia Spies; Jörg Weimann; Gabriele Wöbker; Elke Muhl; Christian Waydhas
Journal:  Ger Med Sci       Date:  2017-08-01

7.  Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study.

Authors:  Dennis Kühn; Carlos Metz; Frederik Seiler; Holger Wehrfritz; Sophie Roth; Mohammad Alqudrah; André Becker; Hendrik Bracht; Stefan Wagenpfeil; Mathias Hoffmann; Robert Bals; Ulrich Hübner; Jürgen Geisel; Philipp M Lepper; Sören L Becker
Journal:  Crit Care       Date:  2020-11-25       Impact factor: 9.097

8.  Chinese ICU physicians' knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey.

Authors:  Wenchao Mao; Difan Lu; Jia Zhou; Junhai Zhen; Jing Yan; Li Li
Journal:  BMC Med Educ       Date:  2022-03-14       Impact factor: 2.463

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.